Debt-to-equity of Adaptimmune Therapeutics PLC from 30 Sep 2016 to 30 Jun 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Adaptimmune Therapeutics PLC quarterly Debt-to-equity in % history and change rate from 30 Sep 2016 to 30 Jun 2025.
  • Adaptimmune Therapeutics PLC Debt-to-equity for the quarter ending 30 Jun 2025 was -5249%, a 1531% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Adaptimmune Therapeutics PLC Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2025 -5249% -5616% -1531% 30 Jun 2025
Q1 2025 592% +269% +83% 31 Mar 2025
Q4 2024 438% +180% +70% 31 Dec 2024
Q3 2024 391% +161% +70% 30 Sep 2024
Q2 2024 367% +148% +68% 30 Jun 2024
Q1 2024 324% +106% +49% 31 Mar 2024
Q4 2023 258% +64% +33% 31 Dec 2023
Q3 2023 230% +72% +46% 30 Sep 2023
Q2 2023 218% +102% +87% 30 Jun 2023
Q1 2023 218% +134% +160% 31 Mar 2023
Q4 2022 194% +137% +239% 31 Dec 2022
Q3 2022 158% +120% +323% 30 Sep 2022
Q2 2022 117% +84% +257% 30 Jun 2022
Q1 2022 84% +55% +186% 31 Mar 2022
Q4 2021 57% +25% +80% 31 Dec 2021
Q3 2021 37% +4% +12% 30 Sep 2021
Q2 2021 33% -4.5% -12% 30 Jun 2021
Q1 2021 29% -13% -30% 31 Mar 2021
Q4 2020 32% -0.94% -2.9% 31 Dec 2020
Q3 2020 33% +9.2% +38% 30 Sep 2020
Q2 2020 37% 30 Jun 2020
Q1 2020 42% 31 Mar 2020
Q4 2019 33% 31 Dec 2019
Q3 2019 24% 30 Sep 2019
Q4 2017 30% +4.5% +17% 31 Dec 2017
Q3 2017 30% +8.9% +41% 30 Sep 2017
Q2 2017 28% 30 Jun 2017
Q1 2017 28% 31 Mar 2017
Q4 2016 26% 31 Dec 2016
Q3 2016 22% 30 Sep 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.